PREDITORS AND ACCEPTABILITY OF HUMAN PAPILLOMA VIRUS VACCINE UPTAKE AMONG SENIOR SECONDARY SCHOOL STUDENTS IN ILE-IFE
Introduction: Cervical cancer is the second most common cancer in women worldwide and in Nigeria. Human papilloma virus (HPV), has been implicated as the causative agent of cervical cancer. The fact that HPV vaccination can prevent the occurrence of this deadly cancer is well established. Though the vaccine has been licensed in Nigeria since 2008 with widespread availability, it is yet to be included in National immunization program in Nigeria. This study aimed to assess the predictors and acceptability of the HPV vaccine among senior secondary girls in Ile-Ife.
Methods: This descriptive cross-sectional study recruited 400 students randomly selected from various secondary schools in Ife central-local government. The data was collected with the use of a pre-tested interviewer-administered questionnaire on knowledge, attitude, and acceptability of cervical cancer, HPV and HPV vaccine. Data were analyzed using descriptive and inferential statistics.
Results: Most respondents (93.2%) had poor knowledge of cervical cancer, HPV and HPV vaccine. Attitude towards cervical cancer and HPV vaccine was good and the majority (74.5% ) had high acceptability for the HPV vaccine. Only 2.8% of the respondents have been vaccinated. Predictors of acceptability of HPV vaccine were younger age group ((AOR) 4.05 ,CI= 2.30-5.45), good knowledge ((AOR =2.50,CI=2.31-6.83) , mother’ higher level of education (AOR= 1.55, CI=2.62- 4.58 ), perceived fatality of cervical cancer ( AOR=4.13,CI=1.49 – 4.19) and perceived efficacy of the HPV vaccine( AOR=1.57, CI= 0.49 – 3.18).
Conclusions: The knowledge of secondary school girls in the study area on cervical cancer, HPV and HPV vaccine is poor though the HPV vaccine acceptability is high. The high acceptability of the vaccine in this study is a reflection of the willingness of this vulnerable group to learn more about the subject matter. There is the need to create school health programs that will focus on health educating the students on this preventable cancer and the available vaccine. Including HPV vaccine into National immunization program in Nigeria may also improve awareness of cervical cancer and the vaccine uptake.
Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human papilloma virus and related diseases inIndia Summary Report. 2015:12-23.
Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted adsorbed)[Cervarix™]. Drugs. 2008;68(3):359-72.
Olowookere S, Abioye-Kuteyi E, Airewele E, Fasure H, Fayose O, Onakpoma F, et al. Awareness and uptake of human papilloma virus vaccination and cervical cancer screening among female undergraduate students in a tertiary institution in Nigeria. Nigerian Journal of Family Practice. 2012;3(1):27-32.
Muñoz N, Franco EL, Herrero R, Andrus JK, de Quadros C, Goldie SJ, et al. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26(suppl 11):L96-107.
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. Jama. 2007;297(8):813-9.
Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4• 5 years of a bivalent L1 virus-like particle vaccine against human papilloma virus types 16 and 18: follow-up from a randomised control trial. The Lancet. 2006;367(9518):1247-55.
Markowitz LE, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E. Quadrivalent human papillomavirus vaccine. Morbidity and Mortality weekly report. 2007;56(RR-2):1-24.
Mc Cormack PL, Joura EA. Quadrivalent Human Papilloma virus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs. 2010;70(18):2449-74.
Monie A, Hung C-F, Roden R, Wu TC. Cervari: a vaccine for the prevention of HPV 16, 18- associated cervical cancer. Biologics. 2008; 2(1): 97-105.
Mogensen O. Improvement of women's health–HPV vaccination after 16 years of age?: Taylor & Francis; 2009.
Erickson BK, Alvarez RD, Huh WK. Human papillomavirus: what every provider should know. Am J Obstet Gynecol. 2013;208(3):169-75.
Agida TE, Akaba GO, Isah AY, Ekele B. Knowledge and perception of human papilloma virus vaccine among the antenatal women in a Nigerian tertiary hospital. Niger Med J. 2015;56(1):23-7.
Patel MS, Kakkad KM, Patel SV. Human papilloma virus vaccination: recent trends in prevalence and recommendations in India. Journal of SAFOMS. 2014;2(1):26.
Adejuyigbe FF, Balogun M, Sekoni AO, Adegbola AA. Cervical cancer and human papilloma virus knowledge and acceptance of vaccination among medical students in Southwest Nigeria. African Journal
of Reproductive Health. 2015;19 (1): 140-8: erratum. African journal of reproductive health.2015;19(2):139.
Chiang VCL, Wong HT, Yeung PCA, Choi YK, Fok MSY, Mak OI, et al. Attitude, acceptability and knowledge of HPV vaccination among local university students in Hong Kong. Int J Environ Res Public Health. 2016;13(5):E486.
Ezenwa BN, Balogun MR, Okafor IP. Mothers’ human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Womens Health. 2013;5:371-7.
Rashwan H, Lubis SH, Ni KA. Knowledge of cervical cancer and acceptance of HPV vaccination among secondary school students in Sarawak, Malaysia. Asian Pac J Cancer Prev. 2011;12(7):1837-41.
Agius PA, Pitts MK, Smith AM, Mitchell A. Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine. 2010;28(27):4416-22.
Araoye MO. Research methodology with statistics for health and social sciences. 1st Ed. Ilorin: Nathadex Publisher. 2004:25- 120.
Jalani FFM, Rani MDM, Isahak I, Aris MSM, Roslan N. Knowledge, attitude and practice of human papilloma virus (HPV) vaccination among secondary school students in rural areas of Negeri Sembilan, Malaysia. International Journal of Collaborative Research on Internal Medicine & Public Health. 2016;8(6);420-34.
Di Giuseppe G, Abbate R, Liguori G, Albano L, Angelillo I. Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. BJC. 2008;99(2):225-9.
Gottvall M, Larsson M, Höglund AT, Tydén T. High HPV vaccine acceptance despite low awareness among Swedish upper secondary school students. European J Contracept Reprod Health Care. 2009;14(6):399-405.
Onowhakpor A, Omuemu V, Osagie O, Odili C. Human Papilloma Virus vaccination: knowledge, attitude and uptake among female medical and dental students in a tertiary institution in Benin-City, Nigeria. Journal of Community Medicine and Primary Health Care. 2016;28(2):101-8.
Lee A, Ho M, Cheung CKM, Keung VMW. Factors influencing adolescent girls’ decision in initiation for human papillomavirus vaccination: a cross-sectional study in Hong Kong. BMC public
Walsh CD, Gera A, Shah M, Sharma A, Powell JE, Wilson S. Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination. BMC public health. 2008;8(1):368.
Schülein S, Taylor KJ, König J, Claus M, Blettner M, Klug SJ. Factors influencing uptake of HPV vaccination among girls in Germany. BMC public health. 2016;16(1):995.
Brewer NT, Gottlieb SL, Reiter PL, McRee A-L, Liddon N, Markowitz L, et al. Longitudinal predictors of HPV vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis. 2011;38(3):197-204.
Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction–the first five years. Vaccine. 2012;30:F139-48.
Potts A, Sinka K, Love J, Gordon R, McLean S, Malcolm W, et al. High uptake of HPV immunisation in Scotland–perspectives on maximising uptake. Euro Surveill. 2013;18(39):1-10.
- There are currently no refbacks.
Copyright (c) 2019 Funmito Omolola Fehintola, Akintunde Olusegun Fehintola, Olorunfemi Akinbode Ogundele, Caleb Adegbenro, Samuel Olowookere, Olusegun Temitope Afolabi
This work is licensed under a Creative Commons Attribution 4.0 International License.